BACKGROUND: Many African Americans carry an amyloidogenic transthyretin mutation (TTR V122I), with a high risk for cardiac TTR amyloid deposition after the age of 65 years. We wished to determine the allele frequency and its clinical penetrance in community-dwelling African Americans. METHODS: Five thousand consenting African Americans, aged 41 to 93 years, in 2 community studies of cardiovascular risk (CHS and ARIC) were included in the study. The following were performed: genotyping of banked DNA for TTR V122I allele status and review of cardiovascular and demographic parameters in CHS and ARIC databases, with statistical comparisons of the frequency of congestive heart failure, survival, and occurrence of features of cardiac amyloidosis in carriers of the amyloidogenic allele and controls. RESULTS: One hundred nineteen (3.23%) of 3,712 ARIC and 17 (2.12%) of 805 CHS African Americans carried TTR V122I. After the age of 65 years (CHS), the frequencies of congestive heart failure (38% vs 15%, relative risk 2.62, P = .04) and mortality (76% vs 53%, relative risk 1.46, P = .08) were higher in V122I allele carriers than in age-, gender- and ethnically matched controls. In ARIC (all subjects <65 years old), there were no differences between carriers and noncarriers in mortality, frequency of congestive heart failure, or findings consistent with cardiac amyloidosis. CONCLUSIONS: Heterozygosity for the amyloidogenic TTR V122I mutation is relatively common in community-dwelling African Americans. Before the age of 65 years, the allele has no discernible impact on cardiac function or mortality. After the age of 70 years, carriers show a higher frequency of congestive failure and greater mortality with more echocardiographic evidence suggestive of cardiac amyloidosis, findings consistent with age-dependent clinical penetrance of this autosomal dominant gene. 2010 Mosby, Inc. All rights reserved.
BACKGROUND: Many African Americans carry an amyloidogenic transthyretin mutation (TTRV122I), with a high risk for cardiac TTR amyloid deposition after the age of 65 years. We wished to determine the allele frequency and its clinical penetrance in community-dwelling African Americans. METHODS: Five thousand consenting African Americans, aged 41 to 93 years, in 2 community studies of cardiovascular risk (CHS and ARIC) were included in the study. The following were performed: genotyping of banked DNA for TTRV122I allele status and review of cardiovascular and demographic parameters in CHS and ARIC databases, with statistical comparisons of the frequency of congestive heart failure, survival, and occurrence of features of cardiac amyloidosis in carriers of the amyloidogenic allele and controls. RESULTS: One hundred nineteen (3.23%) of 3,712 ARIC and 17 (2.12%) of 805 CHS African Americans carried TTRV122I. After the age of 65 years (CHS), the frequencies of congestive heart failure (38% vs 15%, relative risk 2.62, P = .04) and mortality (76% vs 53%, relative risk 1.46, P = .08) were higher in V122I allele carriers than in age-, gender- and ethnically matched controls. In ARIC (all subjects <65 years old), there were no differences between carriers and noncarriers in mortality, frequency of congestive heart failure, or findings consistent with cardiac amyloidosis. CONCLUSIONS: Heterozygosity for the amyloidogenic TTRV122I mutation is relatively common in community-dwelling African Americans. Before the age of 65 years, the allele has no discernible impact on cardiac function or mortality. After the age of 70 years, carriers show a higher frequency of congestive failure and greater mortality with more echocardiographic evidence suggestive of cardiac amyloidosis, findings consistent with age-dependent clinical penetrance of this autosomal dominant gene. 2010 Mosby, Inc. All rights reserved.
Authors: Alexander P Reiner; Elad Ziv; Denise L Lind; Caroline M Nievergelt; Nicholas J Schork; Steven R Cummings; Angie Phong; Esteban González Burchard; Tamara B Harris; Bruce M Psaty; Pui-Yan Kwok Journal: Am J Hum Genet Date: 2005-01-19 Impact factor: 11.025
Authors: D W Kitzman; J M Gardin; J S Gottdiener; A Arnold; R Boineau; G Aurigemma; E K Marino; M Lyles; M Cushman; P L Enright Journal: Am J Cardiol Date: 2001-02-15 Impact factor: 2.778
Authors: R H Falk; J F Plehn; T Deering; E C Schick; P Boinay; A Rubinow; M Skinner; A S Cohen Journal: Am J Cardiol Date: 1987-02-15 Impact factor: 2.778
Authors: Marios Arvanitis; Clarissa M Koch; Gloria G Chan; Celia Torres-Arancivia; Michael P LaValley; Daniel R Jacobson; John L Berk; Lawreen H Connors; Frederick L Ruberg Journal: JAMA Cardiol Date: 2017-03-01 Impact factor: 14.676
Authors: Keyur B Shah; Anit K Mankad; Adam Castano; Olakunle O Akinboboye; Phillip B Duncan; Icilma V Fergus; Mathew S Maurer Journal: Circ Heart Fail Date: 2016-06 Impact factor: 8.790
Authors: Mamoun M Alhamadsheh; Stephen Connelly; Ahryon Cho; Natàlia Reixach; Evan T Powers; Dorothy W Pan; Ian A Wilson; Jeffery W Kelly; Isabella A Graef Journal: Sci Transl Med Date: 2011-08-24 Impact factor: 17.956
Authors: Sravan C Penchala; Stephen Connelly; Yu Wang; Miki S Park; Lei Zhao; Aleksandra Baranczak; Irit Rappley; Hannes Vogel; Michaela Liedtke; Ronald M Witteles; Evan T Powers; Natàlia Reixach; William K Chan; Ian A Wilson; Jeffery W Kelly; Isabella A Graef; Mamoun M Alhamadsheh Journal: Proc Natl Acad Sci U S A Date: 2013-05-28 Impact factor: 11.205